SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported)October 26, 1995
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-1822 25-1229323
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) ( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On October 26, 1995, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that its subsidiary, Diasense,
Inc., has received a $32.5 million contract from IMACO
Gesellschaft fur Non Invasive Systeme, GmbH (IMACO) for
the Diasensor 1000 noninvasive glucose sensor for
diabetics.
The agreement, which is supported by Irrevocable
Letters of Credit, gives Saalfeld, Germany-based IMACO
exclusive distribution in Germany of the Diasensor 1000
and requires IMACO to purchase a total of 5,100
machines in 1996.
IMACO Saalfeld's parent company IMACO Lubeck, has
been in medical equipment distribution for years
(specializing in diabetic equipment). IMACO will have
full responsibility for the marketing costs of the
machines purchased.
The patented Diasensor 1000, the world's first
noninvasive glucose sensor, will eliminate the
inconvenience and discomfort of finger pricks now
necessary for diabetics to measure their glucose levels
with currently available invasive glucose meters.
Diasensor 1000 uses infrared light to measure the
glucose levels in a diabetic's tissue without the need
to draw blood.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: October 26, 1995
